Hollander N
J Immunol. 1984 Nov;133(5):2801-5.
Monoclonal antibodies against the T cell differentiation antigen Lyt-1 were effective in the therapy of transplanted mouse tumors. A possible mechanism whereby anti-Lyt-1 antibodies directly bind and affect the tumor cells was excluded by the following findings: a) growth of lymphoid and nonlymphoid tumors (which lack Lyt-1 antigen) was affected by anti-Lyt-1 antibodies; and b) the curative effect of passively administered anti-Lyt-1 anti-bodies was abrogated in mice depleted of T cells, supporting a mechanism whereby host Lyt-1+ cells were involved in tumor therapy. Treatment with anti-Lyt-1 antibodies was not accompanied by depletion of Lyt-1+ cells from lymphoid organs, indicating that the administered antibodies altered Lyt-1+ cell functions without affecting their frequency. In view of the in vitro enhancing effects of anti-Lyt-1 antibodies on a variety of immune responses (including lymphokine secretion and generation of cytotoxic T cell), it is suggested that the potentiation of Lyt-1+ cell activity by passively administered anti-Lyt-1 antibodies results in tumor rejection.
针对T细胞分化抗原Lyt-1的单克隆抗体在移植性小鼠肿瘤治疗中有效。以下发现排除了抗Lyt-1抗体直接结合并影响肿瘤细胞的一种可能机制：a）抗Lyt-1抗体影响淋巴样和非淋巴样肿瘤（缺乏Lyt-1抗原）的生长；b）在T细胞耗竭的小鼠中，被动给予的抗Lyt-1抗体的治疗效果被消除，这支持了宿主Lyt-1+细胞参与肿瘤治疗的一种机制。用抗Lyt-1抗体治疗并未伴随淋巴器官中Lyt-1+细胞的耗竭，这表明所给予的抗体改变了Lyt-1+细胞的功能而不影响其频率。鉴于抗Lyt-1抗体在体外对多种免疫反应（包括淋巴因子分泌和细胞毒性T细胞的产生）具有增强作用，提示被动给予的抗Lyt-1抗体增强Lyt-1+细胞活性导致肿瘤排斥。
